We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

90 hedge funds and large institutions have $199M invested in BioSpecifics Technologies Corp. in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

1% more funds holding

Funds holding: 8990 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 34

22% less capital invested

Capital invested by funds: $255M → $199M (-$56.2M)

Holders
90
Holders Change
+1
Holders Change %
+1.12%
% of All Funds
2.24%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
34
Reduced
34
Closed
6
Calls
Puts
Net Calls
Net Calls Change

BSTC Hedge Fund Activity: Q2 2017 in Review

90 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q2 2017, worth a combined $199M — down 22% from $255M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BSTC positions and 6 closed out — a net gain of 1 holder — while 34 added to existing stakes and 34 trimmed.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $3.14M. The largest seller was Numeric Investors, cutting an estimated $2.74M.

  • 90 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q2 2017, up from 89 in Q1 2017.
  • Funds reported $199M of BioSpecifics Technologies Corp. stock for Q2 2017, down 22% quarter-over-quarter.
  • 7 funds opened new BioSpecifics Technologies Corp. positions in Q2 2017 and 6 closed out, a net change of +1 holder.
  • The largest BioSpecifics Technologies Corp. buyer in Q2 2017 was Stonepine Capital Management, an estimated $3.14M added.
  • The largest BioSpecifics Technologies Corp. seller in Q2 2017 was Numeric Investors, an estimated $2.74M sold.

Based on aggregated 13F filings for Q2 2017.